Phase 3 registered trials
- Reported quantity
- 1.75 mg subcutaneously
- Frequency
- As-needed, with trials limiting frequency to no more than 8 per month
- Study duration
- 24-week trial period
1.75 mg is the figure the entire pivotal programme settled on.
Protocols · Cosmetic
PT-141: literature-reported ranges
PT-141 completed a full registered development programme and its phase 3 data is public, which makes the reported figures here unusually well characterised for a compound sold as a research peptide.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- Selective MC4R agonist
- Reported half-life
- Approximately 2.7 hours
- Routes used in the literature
- Subcutaneous in the registered programme; intranasal in earlier abandoned arms
- Also written as
- Bremelanotide
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Earlier intranasal dose-ranging
- Reported quantity
- 7.5–20 mg intranasally
- Frequency
- As-needed
- Study duration
- Single administration studies
The intranasal route was dropped after blood-pressure findings.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
PT-141 · 10 mg Vial
PT-141 is dosed at 500 mcg–1.5 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
- Typical daily range
- 500–1500 mcg once daily (gradual titration over 16 weeks).
- Easy measuring
- At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 | 1500 mcg (1.5 mg) | 45 units (0.45 mL) |
Mixed with 3 ml of bacteriostatic water
The same arithmetic for every vial size PT-141 is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
PT-141 · 3 ml bacteriostatic water
| Vial size | Concentration | Per 1 unit | 500 mcg = | 1.50 mg = |
|---|---|---|---|---|
| 10 mg | 3.33 mg/ml | 33 mcg | 15 units | 45 units |
Unit columns use the range reported for this compound (500 mcg–1.50 mg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
A 10 mg vial in 2 mL of bacteriostatic water gives 5 mg/mL; 0.35 mL draws 1.75 mg.
Open the reconstitution calculatorHow to read these figures
- Transient blood-pressure elevation is documented across the programme and drove the route change.
- Nausea was the most frequently reported finding in the pivotal trials.
- Melanocortin agonists have overlapping activity at multiple receptor subtypes.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
- [1]Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA, Clayton AH, Portman D, et al. · Obstet Gynecol · 2019 · PMCID PMC6819021
Premenopausal women with HSDD self-administered subcutaneous bremelanotide 1.75 mg as needed (at least 45 minutes before anticipated sexual activity) in two phase 3, randomized, placebo-controlled trials over 24 weeks.
View the record - [2]Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Simon JA, Kingsberg SA, Portman D, et al. · Obstet Gynecol · 2019 · DOI 10.1097/AOG.0000000000003514
Open-label extension study in which women self-administered subcutaneous bremelanotide 1.75 mg as needed for up to 52 weeks to evaluate long-term safety.
View the record
Search the databases yourself
Read the PT-141 research briefOther cosmetic compounds
AHK-CuCopper-binding tripeptide (Ala-His-Lys)Melanotan ILinear α-MSH analogue, selective MC1R agonistMelanotan IICyclic α-MSH analogueSnap-8SNAP-25 mimetic octapeptide
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.